Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Proellex achieves statistically significant pain reduction in endometriosis

Dec. 20, 2006

Alliance gets French go-ahead for phase II trial of Oxygent

Dec. 20, 2006

Advisory Committee recommends alternative phase II study for Hemopure

Dec. 20, 2006

Nippon Shinyaku and Roche terminate NS-220 license agreement

Dec. 20, 2006

FDA approval for Bio-E-Gel, to be marketed as Elestrin

Dec. 19, 2006

Roche files additional Mircera data

Dec. 19, 2006

AT-2220 begins phase I studies for Pompe disease

Dec. 19, 2006

OSI grants Bristol-Myers Squibb license for DPP-IV inhibitors

Dec. 19, 2006

NeurotrophinCell shows potential for prevention of type 1 diabetes

Dec. 19, 2006

Reliant seeks to expand use of Omacor

Dec. 18, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...